Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 4
1976 36
1977 26
1978 69
1979 131
1980 87
1981 88
1982 112
1983 124
1984 84
1985 89
1986 78
1987 102
1988 106
1989 104
1990 91
1991 87
1992 62
1993 65
1994 42
1995 35
1996 25
1997 20
1998 28
1999 31
2000 34
2001 26
2002 26
2003 21
2004 31
2005 26
2006 36
2007 31
2008 48
2009 44
2010 42
2011 52
2012 53
2013 46
2014 54
2015 60
2016 57
2017 58
2018 50
2019 60
2020 68
2021 50
Text availability
Article attribute
Article type
Publication date

Search Results

2,604 results
Results by year
Filters applied: . Clear all
Page 1
Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
MacCarthy EP, Bloomfield SS. MacCarthy EP, et al. Pharmacotherapy. 1983 Jul-Aug;3(4):193-219. doi: 10.1002/j.1875-9114.1983.tb03252.x. Pharmacotherapy. 1983. PMID: 6310529 Review.
Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. ...Labetalol administered alone or with a diuretic is often effective when other antihypertensive regimens have failed. ...
Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. ..
Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial.
Sharma KJ, Greene N, Kilpatrick SJ. Sharma KJ, et al. Hypertens Pregnancy. 2017 Feb;36(1):44-47. doi: 10.1080/10641955.2016.1231317. Epub 2016 Oct 27. Hypertens Pregnancy. 2017. PMID: 27786578 Clinical Trial.
Minor side effects were significantly more common in women taking nifedipine compared to labetalol (48% versus 20%, p = 0.04). CONCLUSIONS: Both labetalol and nifedipine were effective for control of persistent postpartum hypertension. ...term=labetalol+versu …
Minor side effects were significantly more common in women taking nifedipine compared to labetalol (48% versus 20%, p = 0.04). CONCLU …
Labetalol.
Carter BL. Carter BL. Drug Intell Clin Pharm. 1983 Oct;17(10):704-12. Drug Intell Clin Pharm. 1983. PMID: 6354658 Review.
Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors. ...Reductions in heart rate are less pronounced with labetalol as compared with propranolol. Labetalol produces rapid reductions in blood pressure when administered i
Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors. ...Reductions in heart rate are less pro
Retrospective evaluation of labetalol as antihypertensive agent in dogs.
Zublena F, De Gennaro C, Corletto F. Zublena F, et al. BMC Vet Res. 2020 Jul 24;16(1):256. doi: 10.1186/s12917-020-02475-4. BMC Vet Res. 2020. PMID: 32709242 Free PMC article.
The clinical records of dogs receiving intra or postoperative labetalol infusion were retrospectively reviewed. Invasive systolic (SAP), mean (MAP) and diastolic (DAP) arterial pressure and heart rate (HR) before labetalol infusion (T0) and 15, 30, 45 and 60 min (T1 …
The clinical records of dogs receiving intra or postoperative labetalol infusion were retrospectively reviewed. Invasive systolic (SA …
Clinical pharmacology of labetalol.
Richards DA, Prichard BN. Richards DA, et al. Br J Clin Pharmacol. 1979;8(Suppl 2):89S-93S. Br J Clin Pharmacol. 1979. PMID: 43165 Free PMC article. Review.
1 The clinical pharmacology of labetalol has been evaluated using pharmacological and physiological test methods. 2 Labetalol displaces the log dose-response curves to the right of isoprenaline-induced increases in heart rate, cardiac output and decreases in diastol …
1 The clinical pharmacology of labetalol has been evaluated using pharmacological and physiological test methods. 2 Labetalol
Pharmacological effects of labetalol in man.
Richards DA. Richards DA. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):721-3. Br J Clin Pharmacol. 1976. PMID: 10949 Free article. Review.
1 The pharmacological effects of labetalol have been studied in normal healthy subjects. The results of these studies are reviewed. 2 In the evaluation of the beta-adrenoreceptor-blocking effects of labetalol various indices of beta-adrenoceptor blockade in man were …
1 The pharmacological effects of labetalol have been studied in normal healthy subjects. The results of these studies are reviewed. 2 …
Comparison of labetalol with other anti-hypertensive drugs.
Prichard BN, Richards DA. Prichard BN, et al. Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):41S-47S. doi: 10.1111/j.1365-2125.1982.tb01888.x. Br J Clin Pharmacol. 1982. PMID: 6124265 Free PMC article. Review.
1 The anti-hypertensive effects of labetalol have been compared and contrasted with other groups of anti-hypertensive drugs in this review of the published literature. 2 The data show that the pharmacological and haemodynamic profile of labetalol in man is distinctl …
1 The anti-hypertensive effects of labetalol have been compared and contrasted with other groups of anti-hypertensive drugs in this r …
Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
Donnelly R, Macphee GJ. Donnelly R, et al. Clin Pharmacokinet. 1991 Aug;21(2):95-109. doi: 10.2165/00003088-199121020-00002. Clin Pharmacokinet. 1991. PMID: 1884570 Review.
Dilevalol and labetalol are examples of a growing number of new beta-blockers which combine nonselective beta-adrenoceptor antagonism with vasodilator activity. Dilevalol is one of the 4 stereoisomers of labetalol, and is estimated to form approximately 25% of the r …
Dilevalol and labetalol are examples of a growing number of new beta-blockers which combine nonselective beta-adrenoceptor antagonism …
Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.
Goa KL, Benfield P, Sorkin EM. Goa KL, et al. Drugs. 1989 May;37(5):583-627. doi: 10.2165/00003495-198937050-00002. Drugs. 1989. PMID: 2663413 Review.
Since labetalol was first reviewed in the Journal (1978), its scope of therapeutic use has expanded and become better defined. Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties. ...
Since labetalol was first reviewed in the Journal (1978), its scope of therapeutic use has expanded and become better defined. Lab
Distinct outcomes of labetalol exposed infants: case reports and systematic review.
Yang X, Hui L, Long H, Zou L. Yang X, et al. J Matern Fetal Neonatal Med. 2021 Jun;34(12):2012-2018. doi: 10.1080/14767058.2019.1651270. Epub 2019 Sep 11. J Matern Fetal Neonatal Med. 2021. PMID: 31510808 Review.
A systematic literature review was carried out followed by a retrospective analysis on neonatal labetalol withdrawal effects. RESULTS: It was discovered that labetalol withdrawal effects initially cause various degrees of hypotension, hypoglycemia, and bradycardia a …
A systematic literature review was carried out followed by a retrospective analysis on neonatal labetalol withdrawal effects. RESULTS …
2,604 results